Giant cell tumor of bone
- PMID: 25378541
- PMCID: PMC4221376
- DOI: 10.1634/theoncologist.2014-0267
Giant cell tumor of bone
Abstract
The role of enhanced fluorodeoxyglucose F 18 uptake of giant cell tumor of bone (GCTB) should be mentioned in an overview such as that reported by van der Heijden et al., with regard not only to the response to denosumab treatment for unresectable GCTB but also to the clinical implications for the diagnosis of this disease.
Figures
Comment in
-
In reply.Oncologist. 2014 Nov;19(11):1208. doi: 10.1634/theoncologist.2014-0332. Oncologist. 2014. PMID: 25378542 Free PMC article.
Comment on
-
The clinical approach toward giant cell tumor of bone.Oncologist. 2014 May;19(5):550-61. doi: 10.1634/theoncologist.2013-0432. Epub 2014 Apr 9. Oncologist. 2014. PMID: 24718514 Free PMC article. Review.
References
-
- Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: An open-label, phase 2 study. Lancet Oncol. 2010;11:275–280. - PubMed
-
- Shin D-S, Shon O-J, Han D-S, et al. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Ann Nucl Med. 2008;22:603–609. - PubMed
-
- Thomas DM, Skubitz KM. Giant cell tumour of bone. Curr Opin Oncol. 2009;21:338–344. - PubMed
-
- Tubbs WS, Brown LR, Beabout JW, et al. Benign giant-cell tumor of bone with pulmonary metastases: Clinical findings and radiologic appearance of metastases in 13 cases. AJR Am J Roentgenol. 1992;158:331–334. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources